BetterLife Pharma (TSE:BETR) has released an update.
BetterLife Pharma is poised to present groundbreaking preclinical data on its non-hallucinogenic LSD derivative, BETR-001, at the FENS conference in Vienna. These findings suggest BETR-001 could significantly impact neuroplasticity and neurotransmission, offering potential treatments for depression, anxiety, neurodegeneration, and addiction. The company’s focus on developing treatments for neuropsychiatric and neurological disorders positions it as an emerging leader in biotech innovation.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
